Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-02 pm EDT 		5-day change 1st Jan Change
43.7 USD -1.15% Intraday chart for Bristol-Myers Squibb Company -2.24% -14.83%
May. 01 HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
May. 01 Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 150,473 140,172 138,395 159,703 104,403 88,584 - -
Enterprise Value (EV) 1 181,813 174,584 165,982 189,770 131,531 127,896 119,134 114,702
P/E ratio - -15.5 x 20 x 24.4 x 13.3 x -16.5 x 8.24 x 8.05 x
Yield 2.62% 2.97% 3.22% 3.04% 4.5% 5.51% 5.78% 5.93%
Capitalization / Revenue 5.76 x 3.3 x 2.98 x 3.46 x 2.32 x 1.92 x 1.92 x 2.01 x
EV / Revenue 6.95 x 4.11 x 3.58 x 4.11 x 2.92 x 2.78 x 2.58 x 2.6 x
EV / EBITDA 18.3 x 9.64 x 8.1 x 9.43 x 7.52 x 24 x 6.6 x 7.02 x
EV / FCF 25.1 x 13.1 x 10.9 x 15.9 x 10.4 x 9 x 8.52 x 8.82 x
FCF Yield 3.98% 7.62% 9.18% 6.3% 9.62% 11.1% 11.7% 11.3%
Price to Book 2.12 x 3.7 x 3.73 x 5.02 x 3.48 x 4.06 x 3.58 x 3.47 x
Nbr of stocks (in thousands) 2,344,185 2,259,752 2,219,645 2,219,645 2,034,758 2,027,100 - -
Reference price 2 64.19 62.03 62.35 71.95 51.31 43.70 43.70 43.70
Announcement Date 2/6/20 2/4/21 2/4/22 2/2/23 2/2/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 26,145 42,518 46,385 46,159 45,006 46,021 46,166 44,090
EBITDA 1 9,945 18,118 20,493 20,123 17,498 5,318 18,046 16,344
EBIT 1 8,199 17,426 19,830 19,442 16,785 4,059 16,858 15,613
Operating Margin 31.36% 40.98% 42.75% 42.12% 37.3% 8.82% 36.52% 35.41%
Earnings before Tax (EBT) 1 4,975 -6,871 8,098 7,713 8,440 -6,032 10,654 10,374
Net income 1 3,439 -9,015 6,994 6,327 8,025 -5,503 10,245 10,087
Net margin 13.15% -21.2% 15.08% 13.71% 17.83% -11.96% 22.19% 22.88%
EPS 2 - -3.990 3.120 2.950 3.860 -2.644 5.300 5.426
Free Cash Flow 1 7,231 13,299 15,234 11,948 12,651 14,210 13,981 13,006
FCF margin 27.66% 31.28% 32.84% 25.88% 28.11% 30.88% 30.29% 29.5%
FCF Conversion (EBITDA) 72.71% 73.4% 74.34% 59.37% 72.3% 267.21% 77.48% 79.57%
FCF Conversion (Net income) 210.26% - 217.82% 188.84% 157.64% - 136.47% 128.93%
Dividend per Share 2 1.680 1.840 2.010 2.190 2.310 2.406 2.526 2.593
Announcement Date 2/6/20 2/4/21 2/4/22 2/2/23 2/2/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 11,985 11,648 11,887 11,218 11,406 11,337 11,226 10,966 11,477 11,865 11,497 11,175 11,623 11,816 11,673
EBITDA 1 4,832 5,305 7,812 7,424 4,288 5,030 4,268 4,539 3,816 -8,984 4,226 4,420 4,756 - -
EBIT 1 4,670 5,267 5,229 4,836 4,110 4,857 4,251 4,360 3,630 -8,329 4,142 4,044 4,228 4,906 4,630
Operating Margin 38.97% 45.22% 43.99% 43.11% 36.03% 42.84% 37.87% 39.76% 31.63% -70.2% 36.03% 36.19% 36.37% 41.52% 39.66%
Earnings before Tax (EBT) 1 - - 1,958 2,209 1,859 2,770 1,859 2,137 1,674 -11,516 1,909 1,557 1,881 - -
Net income 1 2,372 1,278 1,421 1,606 2,022 2,262 2,073 1,928 1,762 -11,911 1,404 1,336 2,564 - -
Net margin 19.79% 10.97% 11.95% 14.32% 17.73% 19.95% 18.47% 17.58% 15.35% -100.39% 12.22% 11.96% 22.06% - -
EPS 2 1.070 0.5900 0.6600 0.7500 0.9500 1.070 0.9900 0.9300 0.8700 -5.890 0.8101 0.7785 1.255 1.820 1.700
Dividend per Share 2 0.5400 0.5400 0.5400 0.5400 0.5700 0.5700 0.5700 0.5700 0.6000 0.6000 0.6048 0.6081 0.6148 0.6744 0.6744
Announcement Date 2/4/22 4/29/22 7/27/22 10/25/22 2/2/23 4/27/23 7/27/23 10/26/23 2/2/24 4/25/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 31,340 34,412 27,587 30,067 27,128 39,312 30,549 26,118
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 3.151 x 1.899 x 1.346 x 1.494 x 1.55 x 7.392 x 1.693 x 1.598 x
Free Cash Flow 1 7,231 13,299 15,234 11,948 12,651 14,210 13,981 13,006
ROE (net income / shareholders' equity) 24.5% 33% 45.7% 49.4% 51.6% 4.22% 75.9% 64.7%
ROA (Net income/ Total Assets) - 11.9% 14.8% 16% 8.36% -2.56% 12% 10.7%
Assets 1 - -75,809 47,265 39,445 95,989 214,675 85,039 94,043
Book Value Per Share 2 30.30 16.80 16.70 14.30 14.70 10.80 12.20 12.60
Cash Flow per Share 2 4.710 6.220 7.300 6.090 6.670 8.990 8.500 7.570
Capex 1 836 753 973 1,118 1,209 1,099 1,142 1,056
Capex / Sales 3.2% 1.77% 2.1% 2.42% 2.69% 2.39% 2.47% 2.39%
Announcement Date 2/6/20 2/4/21 2/4/22 2/2/23 2/2/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
43.7 USD
Average target price
53.32 USD
Spread / Average Target
+22.01%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-14.83% 89.62B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 699B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 326B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
NOVARTIS AG Stock Novartis AG
+4.71% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 154B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. Financials Bristol-Myers Squibb Company